P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma
Title:
P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma
Author:
Trudel, Suzanne McCurdy, Arleigh Sutherland, Heather Louzada, Martha Venner, Christopher White, Darrell Mian, Hira Kotb, Rami Othman, Ibraheem Camacho, Fernando Fu, Molei Gul, Engin Reece, Donna